Abstract
Beta adrenergic receptor blocking agentsare one of the multi-function classes of the drugs, prescribing to treatvarious cardio-vascular diseases, and at the same time, this class have been mostly discussing for several years due to the number of publications with the critical comments and rule this class of drugs out from priority groups for the treatment of arterial hypertension (AH), as, for example, it took place in the United Kingdom and the United States. However, national guidelines for the diagnosis and treatment of arterial hypertension (AH), as well as the guidelines from the European Society of Hyper- tension keep the same position on the β-blockers, including them on equal ground with list of 5 major classes of antihypertensive drugs to treat AH.
Highlights
Beta adrenergic receptor blocking agentsare one of the multi-function classes of the drugs, prescribing to treatvarious cardio-vascular diseases, and at the same time, this class have been mostly discussing for several years due to the number of publications with the critical comments and rule this class of drugs out from priority groups for the treatment of arterial hypertension (AH), as, for example, it took place in the United Kingdom and the United States
National guidelines for the diagnosis and treatment of arterial hypertension (AH), as well as the guidelines from the European Society of Hypertension keep the same position on the β-blockers, including them on equal ground with list of 5 major classes of antihypertensive drugs to treat AH
Что в частоте развития событий не было разницы между группами принимавших и не принимавших β-АБ в подгруппах с ИБС, а у пациентов с наличием только факторов риска частота осложнений была даже выше на фоне приема β-АБ, в связи с чем были высказаны сомнения в необходимости назначения β-АБ пациентам с хронической ИБС без инфаркта миокарда (ИМ) в анамнезе
Summary
Наряду с диуретиками β-АБ стали первыми препаратами, при лечении которыми было доказано, что антигипертензивная терапия (АГТ) уменьшает риск развития сердечно-сосудистых осложнений (ССО) у больных АГ. Этот метаанализ подтвердил то, что отказываться от β-АБ не следует они оказывают защитное сердечно-сосудистое действие, кроме того, имеют дополнительные преимущества при назначении больным с ИБС после ИМ.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
